CEL-SCI Corporation

Virginia, United States · Biotechnology, Healthcare, Health Care · 43 employees

CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial

Funding history

Series common stock offering — $2.5M — Jun 2026
Funding Round — $10.8M — Jul 2024
Funding Round — Undisclosed — Jul 2017

Recent signals

Jun 14, 2026: SEC 8-K (1.01): On June 14, 2026, CEL-SCI Corporation entered into a Placement Agency Agreement with ThinkEquity LLC to sell 2,500,000 shares of its common stock at an offering price of $1.00 per share. The Offering was closed on June 16, 2026, resulting in gross proceeds of $2,500,000 before deductions for fees and expenses. The proceeds are intended for the development of Multikine, general corporate purposes, and working capital. This transaction represents a significant step in funding the Company’s operational strategies and future projects.
Jun 14, 2026: Raised $2.5M in Series common stock offering
May 11, 2026: CEL-SCI Partners with Amarox for the Distribution and Revenue Sharing of Multikine in Saudi Arabia.
Jul 11, 2025: CEL-SCI Corporation Enters Partnership with Saudi Pharmaceutical Company for Cancer Drug Multikine.
Dec 12, 2024: Launched CEL-SCI Corporation Announces Strong Biological Rationale for Multikine in Head and Neck Cancer Study
Oct 01, 2024: CEL-SCI Renews Partnership with Ergomed for FDA Registration Study of Multikine in Head and Neck Cancer
Jul 29, 2024: Raised $10.8M
Jul 17, 2017: Raised Undisclosed

See plans & pricing → Track CEL-SCI Corporation’s funding, hiring, and signals — with verified contacts — on Fundz.